Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06383273 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)
A Phase 3 study of Cataract, sponsored by Melt Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 528
- Enrollment target
- 12
- Study locations
NCT06383273 is a Phase 3 study of Cataract that is actively recruiting participants, run by Melt Pharmaceuticals. The registered enrollment target is 528 participants, above the 222-participant average among 83 other Cataract trials with a reported enrollment target (138% higher). The trial reports 12 study locations across 11 states.
The verdict
NCT06383273, a Phase 3 study of Cataract, is actively recruiting participants, sponsored by Melt Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 528 participants
- Enrollment target
- 12
- Study locations
Study Summary
The goal of this clinical trial is to learn if MELT-300 works on procedural sedation in adult participants undergoing cataract extraction with lens replacement (CELR). It will also learn about the safety of MELT-300. Researchers will compare MELT-300 to a placebo (a look-alike substance that contains no drug) to see if MELT-300 works on procedural sedation in adult participants undergoing CELR. Researchers will also include a comparator SL midazolam to confirm the benefit of inclusion of ketamine in the combined drug product. The main questions it aims to answer are: 1. Does MELT-300 is effective in comparison to placebo on procedural sedation for cataract surgery? 2. To determine the effectiveness of MELT-300 compared with midazolam on procedural sedation (to determine the contribution of ketamine component and inform the risk of ketamine in MELT-300) 3. To determine the time to achieve preoperative target sedation level with MELT-300 4. What medical problems do participants have when taking MELT-300 vs placebo Eligible participants will admitted to the study unit on Day 1. Participants will be randomized prior to surgery 4:1:1 to 1. MELT-300 (i.e. 1 MELT-300 sublingual tablet which contains 3 mg midazolam and 50 mg of ketamine) 2. Midazolam (i.e. 1 matching midazolam sublingual tablet which contains 3 mg midazolam) 3. Placebo (i.e. 1 matching placebo sublingual tablet) Participants will receive study medication 30 (± 5) minutes, without food or water, before planned surgery start (defined as instillation of topical ocular anesthetic gel \[i.e.. 3 drops of chloroprocaine hydrochloride ophthalmic gel)\]. The effectiveness of MELT-300 will be performed after study medication is administered before surgery, in the course of surgery, and postoperative on Day 1 (end of surgery defined as just prior to drape removal). The safety of MELT-300 will be performed at baseline, in the course of surgery, postoperatively on Day 1, and on Day 3 ± 1 day post dose of study med
Conditions Studied
Interventions
- DRUG MELT-300 sublingual tablet
- DRUG Midalozam sublingual tablet
- DRUG Placebo sublingual tablet
Study Locations (12)
North Dakota
- Bergstrom Eye Research - Fargo
- Vance Thompson Vision, ND - West Fargo
California
- Ridge Eye Care, Inc. - Chico
Colorado
- Icon Eye Care - Grand Junction
Florida
- Levenson Eye Associates - Jacksonville
Maryland
- Maryland Vision Institute - Hagerstown
Minnesota
- Vance Thompson Vision- Alexandria - Alexandria
Mississippi
- Tekwani Vision Center - Bay Saint Louis
Pennsylvania
- Northeastern Eye Institute - Scranton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 528 participants |
| Start Date | 2024-05-01 |
| Est. Completion | 2025-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06383273
The ClinicalTrials.gov registry entry for NCT06383273 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 528 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 222-participant average among 83 other Cataract trials with a reported enrollment target (138% higher). The listed sponsor is Melt Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cataract appearing as the primary indexed condition, and to 3 interventions - of which MELT-300 sublingual tablet is the first listed.
NCT06383273 reports 12 study locations spanning 11 distinct geographic areas - top geographies include North Dakota, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT06383273 about?
NCT06383273 is a clinical study titled "A Study to Evaluate Efficacy and Safety of MELT-300 for Procedural Sedation in Subjects Undergoing Cataract Extraction With Lens Replacement (CELR)". The goal of this clinical trial is to learn if MELT-300 works on procedural sedation in adult participants undergoing cataract extraction with lens replacement (CELR). It will also learn about the safety of MELT-300. Researchers will compare MELT-300 to a placebo (a look-alike substance that contain...
What is the current status of trial NCT06383273?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 528 participants. The study started on 2024-05-01. Estimated completion is 2025-01.
What conditions does trial NCT06383273 study?
This clinical trial studies the following conditions: Cataract.
What interventions are being tested in trial NCT06383273?
The interventions under investigation include: MELT-300 sublingual tablet (DRUG), Midalozam sublingual tablet (DRUG), Placebo sublingual tablet (DRUG).
Who is sponsoring clinical trial NCT06383273?
This trial is sponsored by Melt Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06383273 being conducted?
This trial has 12 study locations across California, Colorado, Florida, Maryland, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cataract
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)
RECRUITING · Phase 3
-
Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)
RECRUITING · Phase 3
-
Safety and Efficacy of a Violet Visible Light Blocking Intraocular Lens (IOL)
COMPLETED · Phase 3
-
Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation
COMPLETED · Phase 3
-
Study of T-PRED(TM) Compared to Pred Forte(R) II
COMPLETED · Phase 3
-
Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.